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ABSTRACT Biosimilars represent a new trend in the treatment of many 
immune-mediated inflammatory diseases. Regulatory requirements 
for approval of biosimilars are different from those of originators and 
rely mostly on the evidence generated from bioequivalence studies 
and in particular from RCTs. Our goal in this review was to search for 
relevant studies from randomized controlled trials on the biosimilars 
adalimumab, etanercept, infliximab and ustekinumab compared with 
their reference medication (publication in Medline) and ongoing stud-
ies in clinical trial registries. For infliximab biosimilars, we found data on 
patients with ankylosing spondylitis rheumatoid arthritis indicating no 
clinically relevant differences regarding efficacy and safety, as well as 
data on inflammatory bowel diseases and psoriasis. In addition, three 
registered studies of adalimumab biosimilars and just one study of an 
etanercept biosimilar were being carried out in patients with psoriasis. 
Ongoing studies on adalimumab, etanercept, and infliximab biosimilars 
in patients with rheumatoid arthritis were also identified. The conclu-
sion seems to be that there are only 4 clinical trials on psoriasis (3 for the 
adalimumab biosimilar and 1 for etanercept biosimilar) and 1 clinical 
trial for Pso, CD, UC, RA, and AS (with the Infliximab biosimilar). Thus, the 
real and unique advantage of biosimilars is the low price derived from 
the special design studies despite the high technology used in fabrica-
tion process. Although not all ongoing biosimilar trials may have been 
registered, the present situation in terms of registered trials is quite un-
satisfactory and provision of further clinical data and inclusion of pa-
tients in patient registries will be crucial.
KEY WORDS: biosimilar, review, clinical trial, biologic, psoriasis, adalim-
umab, etanercept, infliximab, Remsima, Inflectra
INTRODUCTION
The development of biologic drugs has enhanced 
the spectrum of treatments available for immune-
mediated inflammatory diseases. However, despite 
their clear clinical benefit, use of biologics is often 
hindered by their high costs. As the patent for many 
TNF-alpha antagonists has expired or will soon expire, 
the development of biosimilars may lower treatment 
cost and increase patient treatment options.
With the introduction of the first biosimilars we 
also have to introduce new terms such as extrapo-
lation, interchangeability, traceability, and substitu-
tion in order to understand the real concept of bio-
equivalence (1,2). Regarding long-term safety, there 
are some issues with immunogenicity that can occur 
even in later stages (more than a year). 
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The first biosimilar of the monoclonal antibody 
infliximab CT-P13 was approved in September 2013 
by the European Medicines Agency (EMA) under 
the brand name of Remsima and Inflectra (1,2). This 
product was approved for all of Remicade’s indica-
tions, although the comparative clinical trials were 
only conducted in patients with RA and AS (3). The 
patent protection for Enbrel and Humira will expire 
in most European countries on February 1st, 2015 and 
April 16th, 2018, respectively, and several biosimilars 
of etanercept and adalimumab are currently under-
going clinical trials (1-4).
There are many differences among different 
countries regarding criteria for regulatory approval 
of biosimilars. The economic advantage is real, but 
bioequivalence cannot be equated to therapeutic 
equivalence and should be demonstrate with further 
post marketing studies (4).
METHODS
We systematically reviewed published trials on 
the efficacy and safety of biosimilars in the literature 
as well as planned and ongoing trials in registries.
Eligibility criteria
Randomized controlled trials investigating bi-
osimilars compared with their reference drugs (adali-
mumab, etanercept, infliximab, ustekinumab) in 
chronic inflammatory diseases (Pso, PA, CD, UC, AS, 
RA) were included. Non-original data and studies 
with healthy patients were excluded. No language 
restrictions were applied.
Literature search
Published RCTs were searched for in the literature 
by using the Medline (PubMed) database, and the fol-







Search items included various terms used for the 
relevant diseases – ankylosing spondylitis, Crohn’s 
disease, ulcerative colitis, rheumatoid arthritis, pso-
riatic arthritis, and psoriasis vulgaris in combination 
with biosimilars.
Study selection and data extraction
Two reviewers independently screened abstracts/
titles for relevance and extracted data from the full 
texts or from records of the registries. Results were 
compared and differences resolved in discussion and 
by checking the data source.
Available study characteristics of both published 
trials and ongoing trials were retrieved for more de-
tailed analysis. Study characteristics included patient 
characteristics, numbers, phase, disease, intervention, 
the definition of primary and secondary outcomes, 




A total of seventy-two publications were identi-
fied using the eligibility criteria. There were no tri-
als providing data on the treatment of patients with 
psoriasis with biosimilars. Two studies were included, 
both on CT-P13 as a biosimilar to infliximab: PLAN-
ETAS, a pharmacokinetic study on 250 patients with 
AS and PLANETRA, a Phase 3 RCT with 606 patients 
with RA (5,6).
Using a 20% improvement from baseline ACR 
score (ACR20) at week 30 as the primary endpoint and 
additional efficacy, immunogenicity, safety, PK, and 
PD parameters as secondary endpoints, the PLAN-
ETRA study showed the equivalence of CT-P13 with 
infliximab in terms of ACR20 response at week 30 in 
active patients with RA with inadequate response to 
MTX treatment (6,7). Overall, CT-P13 was well toler-
ated, and the safety profile of CT-P13 was comparable 
with that of infliximab.  
The primary outcome of the PLANETAS study was 
pharmacokinetic equivalence, with additional sec-
ondary outcomes such as a 20% improvement from 
baseline in the ASAS group criteria. The equivalence 
in terms of pharmacokinetics as well as clinical effi-
cacy was demonstrated (5,8,9).
The risk of bias was rated as low for both studies 
(5-9).
Planned/ongoing RCTs
One hundred and twenty nine publications were 
identified; seventeen studies were included (Table 1, 
2, 3, 4, 5, and 6).
Adalimumab: there were three completed RCTs 
of two adalimumab biosimilars as well as 3 ongoing 
registered RCTs of 3 adalimumab biosimilars (10-15). 
Two of the completed trials involve the adalimumab 
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biosimilar ABP 501 versus adalimumab (Humira) in 
530 patients with RA and 350 patients with psoriasis 
and one phase 1 trial involving the adalimumab bi-
osimilar BCD-057 in 94 healthy individuals (10,12,14). 
Ongoing trials of adalimumab biosimilars involve 
SB5, M923, and GP2017 versus adalimumab in 490 
patients with RA and 964 patients with psoriasis 
(11,13,15).
Etanercept: there were two completed RCTs of 2 
etanercept biosimilars (CP2015 and HD2013) versus 
etanercept (Enbrel) in 546 patients with psoriasis and 
300 patients with RA, and 2 ongoing RCTs registered 
(16-19). A trial on the etanercept biosimilar SB4 ver-
sus etanercept (Enbrel), including 498 patients with 
RA and a trial on the CHS-0214 biosimilar versus the 
originator in 486 patients with RA were registered 
(17,19). Completion was scheduled for November 
2014 (no published studies) and October 2015, re-
spectively. At present, these studies are in the phase 
of data collection for primary outcome measures.
Infliximab: four ongoing RCTs and one completed 
RCT of infliximab biosimilars were identified (20-23). 
A trial on the infliximab biosimilar SB2 with 584 pa-
tients with RA was registered in August 2013, with a 
scheduled completion date set for November 2014 
(20). No data have been published yet. Another trial 
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using NI-071 in 230 patients with RA, was registered 
in July 2013 (21). The already-approved CT-P13 is cur-
rently involved in 2 ongoing trials involving patients 
with IBD, RA, AS, and psoriasis (22,23).
Ustekinumab: no published or ongoing RCTs in 
patients with psoriasis or other indications were iden-
tified.
DISCUSSION
In the ever-expanding market of biosimilars, it is 
important for us as clinicians to be confident about 
the requirements for the approval of biosimilars. This 
reassurance comes from the evidence that has been 
generated before marketing authorization, and in 
particular from RCTs as an important part of it. Unfor-
tunately, at present there is rather limited evidence 
provided by the clinical trials, especially on psoriasis 
and psoriatic arthritis, which would help a derma-
tologist feel more comfortable about prescribing bi-
osimilars.
For example, the first biosimilar Inflectra or Remsi-
ma was approved for all Remicade’s indications based 
on studies on rheumatoid arthritis and ankylosing 
spondylitis and is being used today in dermatology 
for psoriasis as well as in gastroenterology for inflam-
matory bowel diseases (2-4)..From this experience, 
which is probably still limited in the number of pa-
tients, we can conclude that there is no specific safety 
concern today that was raised and no specific lack of 
efficacy either. There are also ongoing centered post-
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marketing studies regarding biosimilar immunoge-
nicity which is the main concern for biosimilars.
All these considerations are linked to the particu-
larities and differences in the approval process and 
the clinical trials of biosimilars in comparison with 
the originator.
Clinical trials of biosimilars
Requirements for approval of a biosimilar include 
physicochemical, biologic, and preclinical studies to 
establish bioequivalence, with clinical development 
focused on confirming and resolving any remaining 
uncertainties regarding bioequivalence (2,3,24).
Because the experience with the reference prod-
uct serves as the base, the primary goal of biosimilar 
development is to demonstrate that the purity, po-
tency, and safety of the biosimilar are similar to the 
reference product. However, one or more clinical 
studies are required to demonstrate the safety of the 
biosimilar (24-29).
Clinical development of the biosimilar begins with 
studies to demonstrate comparable pharmacokinet-
ics and pharmacodynamics with the reference prod-
uct in a relevant population. Also included in early 
clinical development are investigations that focus on 
safety, including immunogenicity. Once PK, PD, and 
immunogenic similarity to the reference product has 
been demonstrated, at least one phase 3 clinical com-
parability trial is conducted to confirm similar efficacy 
and safety in a sensitive population (24-26).
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Phase 3 clinical comparability trials are intended 
to resolve uncertainties that remain regarding the ef-
ficacy and safety of the biosimilar in comparison with 
the reference product following completion of physi-
cochemical, biologic, and preclinical investigations, as 
well as PK, PD, and immunogenicity investigations in 
humans (28,29). These trials provide a head-to-head 
comparison with the reference product, with the goal 
of demonstrating that the proposed biosimilar has 
neither decreased, nor increased activity relative to 
the reference product. Study design elements must 
be determined carefully as they are critical determi-
nants of detecting clinically meaningful differences 
between the biosimilar and the reference product.
In dermatology, published direct data on patients 
with psoriasis are missing.
However, information on biosimilars in patients 
with psoriasis is currently being investigated in 2 
completed trials involving an Adalimumab biosimilar, 
ABP501, and an etanercept biosimilar – GP2015, with 
results not yet available. Furthermore, there are also 
3 ongoing clinical trials on patients with psoriasis, 
including the already approved infliximab biosimilar 
CT-P13 as well as the adalimumab biosimilars GP2017 
and M923. 
Regarding the already approved infliximab bi-
osimilar CT-P13, clinical data that contributed to its 
approval were generated by PLANETAS and PLAN-
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ETRA, two pivotal randomized clinical trials which 
directly compared CT-P13 and the reference product 
in AS and RA (5,6).. In these randomized clinical tri-
als, the two agents were shown to be highly similar 
in terms of PK, efficacy, and safety. However, post-
marketing surveillance is needed to further evaluate 
the safety profile of this biosimilar, and there are cur-
rently 3 ongoing phase-4 clinical trials involving pa-
tients with psoriasis, RA, AS, CD, and UC. Two of them 
are interventional phase-4 studies, and their purpose 
is to also assess the safety and efficacy of switching 
from Remicade to the biosimilar Remsima in patients 
with rheumatoid arthritis, spondyloarthritis, psoriatic 
arthritis, ulcerative colitis, Crohn’s disease, and chron-
ic plaque psoriasis, with approximately 500 patients 
to be enrolled to assess the efficacy of an infliximab-
biosimilar (Inflectra) compared with an infliximab-
innovator (Remicade) in patients with inflammatory 
bowel disease in remission.
At present there are two post-marketing observa-
tional studies on patients with inflammatory bowel 
diseases, RA, AS, and psoriasis that have been pre-
scribed Inflectra (infliximab) or Remicade (infliximab) 
for treatment.
Our research found that there were no trials on 
biosimilars for ustekinumab.
Table 5. Randomized controlled trial investigating CT-P13 compared to its reference drug
CONCLUSION
For infliximab biosimilars, we found data on pa-
tients with ankylosing spondylitis and rheumatoid 
arthritis that indicated no clinically relevant differ-
ences regarding efficacy and safety, as well as data 
on inflammatory bowel diseases and psoriasis. While 
there were three registered studies of adalimumab 
biosimilars, we found just one study on an etanercept 
biosimilar being carried out in patients with psoria-
sis. Ongoing studies on adalimumab, etanercept, and 
infliximab biosimilars in patients with rheumatoid ar-
thritis were also identified.
As to psoriasis, evidence is currently being sought 
for the adalimumab biosimilars ABP 501, GP2017, and 
M923 in approximately 400 patients, and for the etan-
ercept biosimilar GP2015 in 270 patients. .
Although data regarding RCTs on biosimilars 
is still limited, it have been expanded over the last 
years. Consequently, this will enable the EMA to con-
sider direct evidence from patients with psoriasis in 
the approval of biosimilars in dermatology. The only 
real advantage of biosimilars is the low cost, but this 
consideration cannot allow us to ignore an inferior 
therapeutic result or side effects. Risk management 
protocols and standardization assays are also needed 
for long term follow-up.
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Although not all ongoing biosimilar trials may 
have been registered, the present situation in terms of 
registered trials is quite unsatisfactory and will leave 
clinicians with some degree of uncertainty with re-
spect to their treatment decisions. As a consequence, 
provision of further clinical data and inclusion of pa-
tients in patient registries will be crucial.
Undoubtedly, the advent of biosimilars will re-
duce acquisition costs of treatment and at the same 
time have an impact on the prescribing patterns of 
clinicians and management of patients.  
Abbreviations:
ACR20/50: American College of Rheumatology 
(20% and 50%), ADA: anti-drug antibodies, ASDAS: 
Ankylosing Spondylitis Disease Activity score, BW: 
body weight, m-month/s, MTX: methotrexate, pts: 
patients, PGA: Physician Global Assessment, SD: Stan-
dard Deviation, TEAE: treatment-emergent adverse 
events, w: week, AE: adverse event, BSA: body sur-
face area, DAS 28: disease activity score 28, HRQol: 
health-related quality of life, IGA: investigator’s Glob-
al Assessment, PASI: Psoriasis Area and Severity In-
dex, QW: once weekly, sPGA: static Physician Global 
Assessment, IBD: inflammatory bowel diseases, CD: 
Crohn’s disease, UC: ulcerative colitis, RA: rheumatoid 
arthritis, Pso; psoriasis, AS: ankylosing spondylitis, 
RCT: randomized control trial, PK: pharmacokinetics, 
PD: pharmacodynamics
Table 6. Randomized controlled trial investigating CT-P13 compared with its reference drug 
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